Coherus BioSciences (Coherus BioSciences) Buyback Yield %

: -29.59 (As of Today)

View and export this data going back to 2014. Start your Free Trial

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Coherus BioSciences's current buyback yield was -29.59%.

Coherus BioSciences Buyback Yield % Historical Data

The historical data trend for Coherus BioSciences's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buyback Yield %

-0.64

-3.33

-1.02

-19.19

Coherus BioSciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Buyback Yield %																-	-4.97	-53.12	-11.21	0.11

Competitive Comparison

For the Biotechnology subindustry, Coherus BioSciences's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coherus BioSciences Buyback Yield % Distribution

For the Biotechnology industry and Healthcare sector, Coherus BioSciences's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Coherus BioSciences's Buyback Yield % falls into.

Coherus BioSciences Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Coherus BioSciences's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	71.718)	/	373.67595
	=	-19.19%

Coherus BioSciences's annualized Buyback Yield for the quarter that ended in Dec. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	-0.105)	*	4	/	373.67595
	=	0.11%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Dec. 2023) data.

Coherus BioSciences Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Coherus BioSciences (Coherus BioSciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (NAS:CHRS) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

8C5:Germany

Address

333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065

Website

https://www.coherus.com

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Executives

Dennis M Lanfear	director, officer: President and CEO	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Michael Lee Ryan	director	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Mcdavid Stilwell	officer: Chief Financial Officer	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Bryan J Mcmichael	officer: See Remarks	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, REDWOOD CITY CA 94065
Paul Reider	officer: Chief Commercial Officer	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jill O'donnell-tormey	director	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Charles W. Newton	director	46 FREDRICK AVENUE, ATHERTON CA 94027
Lee Nisley Newcomer	director	264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vladimir Vexler	officer: Chief Scientific Officer	333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Vincent R Anicetti	officer: Chief, Quality & Compliance	COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jean-frederic Viret	officer: Chief Financial Officer	ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Mark Stolper	director	150 COTNER AVENUE, LOS ANGELES CA 90025
Alan C Mendelson	director	ALAN C MENDELSON, 135 COMMONWEALTH DR, MENLO PARK CA 94025
Kimberly Jo Tzoumakas	director	1170 FAIRFAX STREET, BIRMINGHAM MI 48009